---
title: "Akari Therapeutics, Plc (AKTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AKTX.US.md"
symbol: "AKTX.US"
name: "Akari Therapeutics, Plc"
industry: "Biotechnology"
---

# Akari Therapeutics, Plc (AKTX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.akaritx.com](https://www.akaritx.com) |

## Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.69 | 157/604 | - | - | - |
| PB | 0.48 | 32/604 | 1.71 | 1.08 | 0.56 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-05T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 75% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.24 |
| Highest Target | 7.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/AKTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AKTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AKTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.